This study is looking at a new drug called BP1002 for patients with acute myeloid leukemia (AML) that has come back or did not respond to previous treatments. The goal is to find out how safe BP1002 is and how well it works. Participants will receive different doses of BP1002 and some will also get another medicine called decitabine.
This trial is registered as NCT05190471. It is a Phase 1 study, which means it is looking at how well the treatment works and how safe it is. The trial is regulated by the FDA and aims to include about 48 participants.
Who can join
Adults aged 18 and older can join if they have relapsed or refractory AML and have not responded to other treatments. They need to be in good health overall, with normal liver and kidney function. The trial is open to both men and women. The team will check to make sure each person meets all requirements.
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be put into two groups. One group will get BP1002 alone, while the other group will receive BP1002 along with decitabine. Everyone will get the treatment, but the study is not random; participants are assigned based on specific criteria. The study has a plan to gradually increase the dose of BP1002 to find the best amount.
Where
This trial is running at 4 locations in the United States. All of them are currently recruiting.
MD Anderson Cancer Center
Houston, Texas
Recruiting
Scripps Green Hospital
La Jolla, California
Recruiting
UCLA Medical Center
Los Angeles, California
Recruiting
Weill Cornell Medical College - NewYork-Presbyterian Hospital